BiotechTube
Healis Therapeutics

Healis Therapeutics

Cambridge, United States· Est.
healisthera.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Healis Therapeutics is an emerging biotech company developing a novel therapeutic approach for neuropsychiatric conditions using targeted neuromodulation via botulinum toxin. The company's lead program, Tyemvers (CKDB-501), is being developed for Major Depressive Disorder (MDD) and is supported by a supply agreement with CKD Bio and a research collaboration with Massachusetts General Hospital. Healis is building a compelling scientific rationale based on published clinical evidence and is positioning itself to address significant unmet needs in treatment-resistant psychiatry.

PsychiatryNeurology

Technology Platform

Localized botulinum toxin type A (BoNT/A) administration for long-term neuromodulation, targeting the afferent facial feedback loop to influence emotional processing in the brain (e.g., amygdala activity).

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

Healis targets the large and underserved market for treatment-resistant depression with a novel, long-acting therapy that could offer a superior side-effect profile compared to systemic drugs.
Successful proof-of-concept could enable rapid expansion into adjacent neuropsychiatric indications like anxiety and Parkinson's-related depression, leveraging the same core platform.

Risk Factors

The primary risks include the clinical failure of its novel mechanism in formal trials, challenges in convincing the psychiatric community to adopt a localized injectable treatment, and intense competition in the depression therapeutic landscape.
As a pre-revenue private company, it also faces significant financing and execution risks.

Competitive Landscape

Healis competes in the broad antidepressant market dominated by generic SSRIs/SNRIs and newer agents like esketamine and auvelity. Its direct novel mechanism competitors are few, but it faces indirect competition from other neuromodulation approaches (TMS, psychedelics) and large pharma pipelines. Its differentiation lies in the localized, long-duration effect of botulinum toxin.

More companies in United States →